Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

The efficacy of tocilizumab was tested in a randomized, controlled trial involving patients with Covid-19 who had fever, pulmonary infiltrates, or a need for supplemental oxygen. The treatment had no significant effect on disease progression, independence from supplemental oxygen, or death.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 383; no. 24; pp. 2333 - 2344
Main Authors: Stone, John H, Frigault, Matthew J, Serling-Boyd, Naomi J, Fernandes, Ana D, Harvey, Liam, Foulkes, Andrea S, Horick, Nora K, Healy, Brian C, Shah, Ruta, Bensaci, Ana Maria, Woolley, Ann E, Nikiforow, Sarah, Lin, Nina, Sagar, Manish, Schrager, Harry, Huckins, David S, Axelrod, Matthew, Pincus, Michael D, Fleisher, Jorge, Sacks, Chana A, Dougan, Michael, North, Crystal M, Halvorsen, Yuan-Di, Thurber, Tara K, Dagher, Zeina, Scherer, Allison, Wallwork, Rachel S, Kim, Arthur Y, Schoenfeld, Sara, Sen, Pritha, Neilan, Tomas G, Perugino, Cory A, Unizony, Sebastian H, Collier, Deborah S, Matza, Mark A, Yinh, Janeth M, Bowman, Kathryn A, Meyerowitz, Eric, Zafar, Amna, Drobni, Zsofia D, Bolster, Marcy B, Kohler, Minna, D’Silva, Kristin M, Dau, Jonathan, Lockwood, Megan M, Cubbison, Caroline, Weber, Brittany N, Mansour, Michael K
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 10.12.2020
Subjects:
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of tocilizumab was tested in a randomized, controlled trial involving patients with Covid-19 who had fever, pulmonary infiltrates, or a need for supplemental oxygen. The treatment had no significant effect on disease progression, independence from supplemental oxygen, or death.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
A complete list of the BACC Bay Tocilizumab Trial investigators and members of the data and safety monitoring board is provided in the Supplementary Appendix, available at NEJM.org.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2028836